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ABSTRACT
Six gold(III) complexes with esters of cyclohexyl-func-
tionalized ethylenediamine-N,N’-diacetate, general formula 
[AuCl2{(S,S)-R2eddch}]PF6, [(S,S)-eddch = (S,S)-ethylene-
diamine-N,N’-di-2-(3-cyclohexyl)propanoate, R = Me, Et, 
n-Pr, n-Bu, i-Bu, i-Am, 1–6, respectively], were tested against 
cancer cell lines such as human melanoma Fem-x, human 
colon carcinoma LS174T and non-small cell lung carcinoma 
A549 as well as a non-cancerous human embryonic lung 
ﬁ broblasts MRC-5 using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay with the aim of 
assessing in vitro antitumoral activity and selectivity. All 
investigated complexes showed lower cytotoxicity and better 
or similar selectivity in comparison to cisplatin, used as ref-
erence compound. Complex [AuCl2{(S,S)-(i-Am)2eddch}]PF6 
(6) demonstrated the highest activity against Fem-x (IC50 = 
14.98 ± 0.34 μM). Additionally, the same complex expressed 
4.5 times higher selectivity than cisplatin.
Keywords: cytotoxicity, gold(III) complexes, R2edda 
type-ligands, selectivity
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SAŽETAK 
Šest kompleksa zlata(III) sa cikloheksil-funkcionalizo-
vanim estrima etilendiamin-N,N’-diacetata, opšte formule 
[AuCl2{(S,S)-R2eddch}]PF6, ((S,S)-eddch = (S,S)-etilendia-
min-N,N’-di-2-(3-cicloheksil)propanoat, R = Me, Et, n-Pr, 
n-Bu, i-Bu, i-Am, 1–6), ispitivano je na humanim ćelijskim 
linijama malignog melanoma Fem-x, karcinoma debelog 
creva LS174T, karcinoma pluća A549 kao i normalnim ćeli-
jama MRC-5 (fetalni plućni ﬁ broblast) korišćenjem 3-(4,5-di-
metiltiazol-2-yl)-2,5-difeniltetrazolium bromid (MTT) testa 
u cilju procene in vitro antitumorske aktivnosti i selektivno-
sti. Svi ispitivani kompleksi pokazali su manju citotoksičnost 
i bolju ili sličnu selektivnost u odnosu na cisplatinu koja je 
korišćena kao referentna supstanca. Kompleks 6 je pokazao 
najveću aktivnost sa IC50 (Fem-x) vrednošću od 14,98 ± 0,34 
μM. Takođe, isti kompleks pokazuje 4,5 puta veću selektiv-
nost od cisplatine.
Ključne reči: citotoksičnost, zlato(III) kompleksi, R2edda 
tip-liganada, selektivnost
ABBREVIATIONS
A549 - Non-small cell lung carcinoma cell line
Fem-x - Human melanoma cell line
HeLa - Human cervix adenocarcinoma cell line
K562 - Human myelogenous leukemia cell line
LS174T - Human colon carcinoma cell line
MRC-5 - Non-cancerous cell line human embryonic lung 
fibroblast
PBMC - Human peripheral blood mononuclear cells
MTT - 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide
R2edda-type ligand - O,O′-Dialkyl-ethylenediamine-
N,N′-diacetate ester type ligands
R2eddch - O,O′-Dialkyl-(S,S)-ethylenediamine-N,N′-di-2-
(3-cyclohexyl)propanoate ester
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INTRODUCTION
Cancer is a disease of deregulated cellular behavior (1). 
The main processes of cancer treatment in humans are 
surgery, radiation, and chemotherapy. Cancer chemother-
apeutic agents can often provide temporary relief of symp-
toms, give the patient more time and rarely cure. In recent 
years, a lot of research has been conducted to the synthesis 
of potential anticancer drugs (2–4). A successful antican-
cer drug should kill or inactivate cancer cells without caus-
ing excessive damage to normal cells (5, 6). Discovering of 
cisplatin by Rosenberg in the 1970s, platinum complexes 
became one of most commonly explored class of cyto-
statics in anticancer chemotherapy, but only a few are in 
worldwide clinical practice use or in clinical trials (7–10). 
An overview or some currently employed anticancer drugs 
(I–III), in clinical trials (IV, V) platinum-based compounds 
are illustrated in Fig.1.
The accumulation of platinum compounds in the body 
has deleterious effects. The two major problems associat-
ed with the use of cisplatin derivatives are the severe toxic 
side effects (11–15) and the intrinsic or acquired resistance 
manifested in various types of cancers (16). Therefore, in 
recent decades, a large number of new metal-based com-
plexes have been developed and tested (17–19).
Gold complexes have recently gained a considerable at-
tention as a class of antitumor compounds with different 
pharmacodynamics and kinetic properties than cisplatin 
with strong cell growth inhibiting effects (20, 21). Since 
gold(III) is isoelectronic to platinum(II) and both metals 
preferentially generate square planar complexes (d8 sys-
tem) a number of gold(III) complexes were synthesized 
and tested as an alternative to the anticancer drug cisplatin 
(22–27). Due to the fact that the gold(III) has high reduc-
tion potential, a range of strategies has been applied in or-
der to obtain gold(III) complexes with sufficient stability 
under physiologically relevant conditions. These strategies 
are mostly related to appropriate ligand selection, which 
has been shown to be crucial in decreasing the pronounced 
tendency of the gold(III) metal center to be reduced to 
gold(I) or/and metallic gold (28). The chelation of the me-
tallic center with multidentate ligands has shown to en-
hance the stability of the complex (29, 30). 
The mechanisms of action of cytotoxic gold(III) com-
plexes seem to be innovative and substantially different 
from that of cisplatin (31). Indeed, it is well known that 
DNA is a primary target for platinum(II) complexes while 
the gold(III) complexes act by targeting mitochondria of 
cancer cells (32) or by inhibiting the activities of different 
proteins (33, 34). Recently, it was found that thiol-contain-
ing enzymes, such as thioredoxin reductase (TrxR), can 
play important roles in the mechanisms of action of anti-
cancer gold complexes (33).
Lately, we reported synthesis and characterization of 
gold(III) complexes with esters of cyclohexyl-function-
alized ethylenediamine-N,N’-diacetate, general formulae 
[AuCl2{(S,S)-R2eddch}]PF6, ((S,S)-eddch = (S,S)-ethylene-
diamine-N,N’-di-2-(3-cyclohexyl)propanoate) (Fig. 2) (22). 
The in vitro cytotoxic evaluation of the investigated 
complexes against tumor cell lines: human adenocarcinoma 
HeLa, human myelogenous leukemia K562 and against nor-
mal stimulated and nonstimulated peripheral blood mono-
nuclear cells PBMC, showed that the cytotoxic action of 
gold(III) complexes with cyclohexyl-functionalized ethyl-
enediamine-N,N’-diacetate esters, (R= i-Bu, i-Am), is fairly 
comparable to that of cisplatin (22). Additionally, it was 
found that these complexes reduce to gold(I) species in two 
steps through short-living intermediate gold(II) (35). This is 
very important because it is believed that the cytotoxic ac-
tivity of gold(III) complexes comes from appropriate gold(I) 
species produced by gold(III) reduction in vivo (24, 35). 
Inspired by these promising results we are deeply inter-
ested in further investigations related to the in vitro antip-
roliferative activity of [AuCl2{(S,S)-R2eddch}]PF6 complex-
es against other cancer cell lines such as human melanoma 
Fem-x, human colon carcinoma LS174, and non-small cell 
lung carcinoma A549 as well as a non-cancerous cell line 
human embryonic lung fibroblast MRC-5.
Figure 1. Th e structure of platinum complexes: Cisplatin (I); Carboplatin 
(II); Oxaliplatin (III); Satraplatin (IV); Tetraplatin (V) Figure 2. [AuCl2{(S,S)-R2eddch}]PF6 complexes
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MATERIALS AND METHODS
Complexes 
Gold(III) complexes were synthesized according to lit-
erature procedure. Shortly, Na[AuCl4] was reacted with with 
an equimolar amount of corresponding ligands, methyl, 
ethyl, n-propyl, n-butyl, isobutyl and isoamyl esters of (S,S)-
ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoic acid 
resprectively (22). Each ligand was suspended in metha-
nol, deprotonated with LiOH∙H2O and after stirring of 1h, 
a solution of Na[AuCl4]∙2H2O in methanol was added. The 
desired complexes were obtained after addition of ammo-
nium hexafluorophosphate. Purity and constitution of the 
obtained products were confirmed with elemental analysis, 
1H and 13C NMR as well as UV/Vis spectroscopies and mass 
spectrometry. As examples for analytical and spectroscopic 
data for complex [AuCl2{(S,S)-iAm2eddch}]PF6 is provided 
(22). Numeration of carbon atoms is shown in Fig. 2.
[AuCl2{(S,S)-iAm2eddch}]PF6 (22): Yield: 66 mg, 57%. 
Anal. Calcd for C30H56N2O4AuCl2PF6: C, 39.09; H, 6.12; N, 
3.04%. Found: C, 38.98; H, 6.13; N, 3.11%. 1H NMR (200 
MHz, CDCl3): δ 0.95 (d, (CH3)2CHCH2CH2–OOC–, 12H; 
m, C7H2, 4H), 1.24 (m, C5,6H2, 8H), 1.50-1.90 (m, C3H2, C4H, 
C5,6H2, (CH3)2CHCH2CH2–OOC– and (CH3)2CHCH2CH2–
OOC–, 20H), 3.43 (m, C8H2, 4H), 3.92 (m, C2H, 2H), 4.30 
(m, (CH3)2CHCH2CH2–OOC–, 4H), 4.71 (s, NH, 2H). δ 13C 
NMR (50 MHz, CDCl3): 11.1 ((CH3)2CHCH2CH2–OOC–), 
16.3 ((CH3)2CHCH2CH2–OOC–), 22.3 ((CH3)2CHCH-
2CH2–OOC–), 25.9 (C6), 32.4 (C4), 33.1 (C7), 33.8 (C5), 36.9 
(C3), 44.5 (C8), 59.2 (C2), 65.8 ((CH3)2CHCH2–OOC–), 
171.0 (C1). IR (ATR): νmax = 2929, 2854, 1731, 1453, 1260, 
1212, 851 cm–1; UV/Vis (CHCl3): λmax (ε, 6630 M–1 cm–1) 
320.95 nm; ESI–MS (CH3CN), positive: m/z: 775.33 [M]+, 
776.33 [M + H]+.
Preparation of drug solutions
 
The stock solutions of the investigated gold(III) com-
plexes were prepared freshly in DMSO (Sigma-Aldrich, 
St. Louis, MO, USA) at the concentrations of 1 mM, and 
immediately diluted by nutrient medium to various work-
ing concentrations. Nutrient medium was RPMI-1640 
(Sigma-Aldrich, St. Louis, MO, USA) supplemented with 
10% fetal bovine serum (FBS; Biochrom AG, Berlin, Ger-
many) and 1% penicillin/streptomycin (Sigma-Aldrich St. 
Louis, MO, USA).
Cell lines
Human melanoma Fem-x, human colon carcinoma 
LS174T, non-small cell lung carcinoma A549 cell lines, and 
non-cancerous human embryonic lung fibroblasts MRC-5 
were grown in nutrient medium.
Determination of cell survival
Target cells Fem-x (5000 cells/well), LS174T (7000 
cells/well), A549 (5000 cells/well), and non-cancerous 
MRC-5 (5000 cells/well) were seeded into the wells of 
a 96-well flat-bottomed microtitre plate. After 24 h, 
different working concentrations of investigated com-
pounds were added to the wells, except for the controls, 
where only the complete medium was added. The final 
concentration range used in the experiments was 1–200 
μM (gold(III) complexes: 12.50, 25, 50, 100, and 200). 
Cisplatin was used as the positive control, and the final 
concentrations were 2.08, 4.17, 8.33, 16.67, and 33.3 μM. 
The final concentration of DMSO never exceeded 0.5%, 
which is a non-toxic concentration for the cells. Culture 
medium with corresponding concentrations of investi-
gated compounds, but without cells, was used as blank. 
The cultures were incubated for 72 h, and the effects of 
the investigated compounds on cancer cell survival were 
determined using the microculture tetrazolium test 
(MTT), according to Mosmann (36) with modification 
by Ohno and Abe (37). Briefly, 20 mL of MTT solution 
(5 mg/mL of phosphate-buffered saline, PBS) was added 
to each well. Samples were incubated for additional 4 
h at 37 °C in a humidified atmosphere of 5% CO2 (v/v). 
Afterward, 100 mL of 100 g/L sodium dodecyl sulfate 
(SDS) was added in order to extract the insoluble forma-
zan, which represents the product of the conversion of 
the MTT dye by viable cells. The number of viable cells 
in each well is proportional to the intensity of the absor-
bance (A) of light, which was measured in an enzyme-
linked immunosorbent assay (ELISA) plate reader at 570 
nm, 24 h later. IC50 values (±SD) were calculated using 
four-parameter logistic function and presented as mean 
from three independent experiments.  IC50 is defined as 
the concentration of an agent inhibiting cell survival by 
50% compared to the vehicle-treated control. As posi-
tive control cisplatin was used. All experiments were 
performed in triplicate.
RESULTS 
The cytotoxic activity of the six investigated gold(III) 
complexes was evaluated in comparison with cisplatin 
against three different cell lines: human melanoma Fem-
x, human colon cancer LS174T, and non-small cell lung 
carcinoma A549, as well as normal non-cancerous cell 
line MRC-5. The results of in vitro cytotoxic activity are 
expressed as IC50 and presented in Table 1. The repre-
sentative graphs showing the action of various concen-
trations of investigated complexes on Fem-x, LS174T, 
A549, and non-cancerous MRC-5 cell survival, deter-
mined by MTT test, upon 72 h of continuous agent ac-
tion are shown in Fig. 3. Additionally, selectivity indices 
are presented in Table 2.
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DISCUSSION 
The cytotoxic action of all investigated gold(III) com-
plexes (Table 1), was the most pronounced against human 
melanoma Fem-x cells and showed the significant cytotox-
icity. In comparison, tested complexes show the moder-
ate cytotoxicity on the A549 and LS174T cells that does 
not differ significantly. The order of the sensitivity of the 
examined malignant cell lines toward gold(III) complexes 
was: Fem-x > LS174T > A549. 
The replacement of methyl by ethyl group in ester moi-
ety (1 → 2) led to increased cytotoxic activity of investi-
gated complexes against LS174T and A549 cell lines, while 
the cytotoxic activity against Fem-x and non-malignant 
cells slightly decreased. The substitution of ethyl with n-
propyl group (2 → 3) in gold(III) complexes decreased 
antiproliferative action against all examined cell lines ex-
cept MRC-5 cells. Further substitution of n-propyl with 
n-butyl (3 → 4) led to enhancement of cytotoxic action 
against Fem-x cells, whereas in all other cases complexes 
showed lower activity. Complex with isobutyl ester moi-
ety, 5, have shown similar cytotoxicity in comparison to 4 
against Fem-x, LS174T, and MRC-5 cell lines. On the other 
hand, the same complex exhibited a stronger antiprolifera-
tive effect against A549 cells. Interestingly, complex 6 ex-
pressed the highest activity against Fem-x, but it was found 
to be the least effective against LS174T and A549 cell lines. 
Generally, all examined complexes exhibited several times 
weaker activity than the reference compound cisplatin. 
Herein examined gold(III) complexes have shown lower 
Table 1. Concentrations of compounds that induced a 50% decrease in 
Fem-x, LS174T, A549, and MRC-5 cell survival rate [expressed as IC50 
(μM)]. Th e cells were incubated with the compounds for 72 h
compounds IC50 [μM]Fem-x LS174T A549 MRC-5
1 23.67 ± 2.44 42.38 ± 2.41 64.91 ± 0.58 194.25 ± 3.73
2 25.16 ± 2.75 37.69 ± 0.38 45.71 ± 1.22 >200
3 28.28 ± 1.24 48.71 ± 0.96 57.86 ± 1.74 182.51 ± 2.66
4 19.77  ± 1.95 55.39 ± 1.28 68.32 ± 0.39 >200
5 21.36  ± 1.62 48.56 ± 0.86 52.18 ±1.54 188.49 ± 3.28
6 14.98  ± 0.34 72.54  ± 2.41 75.22 ±0.63 >200
cisplatin 4.82 ± 0.35 4.27 ± 0.57 10.92 ± 1.38 14.11 ± 0.72
Table 2. Selectivity indices 
compounds IC50 (MRC-5)/IC50 (tumor cell line)Fem-x LS174T A549
1 8.21 ± 0.86 4.58 ± 0.28 2.99 ± 0.06
2 > 7.95 > 5.31 > 4.38
3 6.45 ± 0.38 3.75 ± 0.09 3.15 ± 0.11
4 > 10.12 > 3.61 > 2.93
5 8.82  ± 0.69 3.88 ± 0.10 3.61 ±0.12
6 > 13.35 > 2.76 > 2.66
cisplatin 2.93 ± 0.26 3.30 ± 0.47 1.29 ± 0.18
Figure 3. Th e survival of Fem-x, LS174T, A549 and MRC-5 cells incubated for 72 h with diﬀ erent concentrations 
of investigated gold(III) complexes (MTT assay)
activity against Fem-x, LS174T and A549 than on human 
cervix adenocarcinoma HeLa and human myelogenous 
leukemia K562 tumor cell lines, reported previously (22). 
Furthermore, it is important to note that the investigated 
complexes showed less toxic action against non-cancerous 
MRC-5 cells than on rested and stimulated normal immu-
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nocompetent human peripheral blood mononuclear cells 
(PBMC) (22). This data point out that investigations con-
cerning anticancer agents development require studies in 
diverse types of normal cells. 
Additionally, on adherent cell lines complexes 1–6 exhibit 
significantly lower antitumor activity than on the nonadher-
ent leukemic K562 cells (22). On the other hand, according to 
the rapidly dividing HeLa and Fem-x cells all complexes show 
a very similar, somewhat greater cytotoxicity (22).
Against the non-cancerous lung fibroblasts (MRC-5) all 
tested complexes were significantly less toxic than cispla-
tin. As can be seen from selectivity indices (Table 2) the 
selectivity of these gold(III) complexes is greater or simi-
lar than cisplatin as a reference drug. All complexes dem-
onstrated the lowest selectivity indices on A549 cell lines, 
however 2–3 times higher than that of cisplatin. Complex-
es 1 and 2 showed the highest selectivity toward LS174T 
cells, even more than cisplatin, while for the other com-
plexes it was similar to cisplatin. Considering selectivity of 
all complexes it was greatest toward Fem-x tumor cells. It 
should be noted that complex 6 shows more than 4.5 times 
greater selectivity on Fem-x than cisplatin and therefore it 
is a very promising candidate for further investigation. 
CONCLUSION
The presented results showed that complex 6, from 
all investigated gold(III) complexes, with isoamyl moiety 
in the κ2-N,N’ coordinated bidenatate ester ligand, exhib-
ited the highest antitumor activity against Fem-x cell line 
(IC50 = 14.98±0.34 μM), from three cell lines tested. In vi-
tro results indicate that these agents are cell type specific, 
for instance from the all tested tumor cell lines they ex-
hibit the highest antitumor activity against leukemic K562 
cells. Moreover, their toxicity is also cell type specific, they 
are less toxic against non-cancerous MRC-5 cells than on 
rested or stimulated PBMC. Additionally, the selectivity of 
these gold(III) complexes is similar or several times greater 
(up to 4.5 times) than cisplatin as a reference drug.
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